T. Rowe Price Associates
KYTH

T. Rowe Price Associates’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

T. Rowe Price Associates’s Portfolio KYTH Stock Details KYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-140,892
Closed -$7.07M – 2591
2015
Q1 		$7.07M Sell
140,892
-190,321
-57% -$7.99M ﹤0.01% 1417
2014
Q4 		$11.5M Hold
331,213
– – ﹤0.01% 1286
2014
Q3 		$10.9M Buy
331,213
+10,935
+3% +$385K ﹤0.01% 1285
2014
Q2 		$12.3M Sell
320,278
-47,041
-13% -$1.64M ﹤0.01% 1271
2014
Q1 		$14.6M Buy
367,319
+232,872
+173% +$10.4M ﹤0.01% 1199
2013
Q4 		$5.01M Buy
+134,447
New +$5.58M ﹤0.01% 1432

Other funds holding KYTH

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates's KYTH Position: Q2 2015 in Review

T. Rowe Price Associates sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q2 2015, closing a stake of 140,892 shares — an estimated $7.07M sold.

T. Rowe Price Associates first reported a position in KYTH in Q4 2013 and held it in 6 quarters. The position peaked at $14.6M in Q1 2014. 153 funds tracked by Wall St. Rank hold KYTH as of Q2 2015.

  • T. Rowe Price Associates reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q2 2015 after selling out during the quarter.
  • T. Rowe Price Associates sold 140,892 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q2 2015, an estimated $7.07M.
  • T. Rowe Price Associates first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q4 2013 and held it in 6 quarters.
  • T. Rowe Price Associates's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $14.6M in Q1 2014.
  • 153 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q2 2015.

Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.